Sun Pharma Advanced Research Company Limited — Board Meeting, 10-02-2025: Outcome of Board Meeting

The board meeting outcome included the approval of the financial results for the quarter and nine months ended December 31, 2024. The consolidated revenue totaled ₹1,510 Cr with a loss before tax of ₹(7,944) Cr. Additionally, the board approved the incorporation of a wholly-owned subsidiary, with specific details to be communicated upon finalization. The company has acknowledged ongoing cash losses and a provision of ₹1,100 Cr related to closing a Parkinson's Disease program.